Form 4: Zimmer Biomet CEO Ivan Tornos Reports Stock Transactions

Zimmer Biomet's CEO, Ivan Tornos, reports the vesting and subsequent sale of shares to cover tax obligations related to restricted stock units.

Summary

• On February 20, 2025, Ivan Tornos, the President and CEO of Zimmer Biomet Holdings, Inc., reported transactions involving the company's common stock.
• Specifically, 15,996 shares were acquired through the vesting of restricted stock units (RSUs).
• Simultaneously, 8,846 shares were disposed of to satisfy tax withholding obligations at a price of $103.46 per share.
• Following these transactions, Tornos directly owns 47,164 shares of Zimmer Biomet common stock.
• He also holds 31,991 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions, so the sentiment is neutral.

Future Outlook

The remaining RSUs held by Ivan Tornos will vest in two tranches on February 20, 2026 and February 20, 2027.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider and is typical for executives who receive stock-based compensation.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry often include restricted stock units (RSUs) that vest over time.
• The vesting schedules and tax withholding practices observed in this filing are consistent with standard practices among publicly traded companies like Medtronic, Stryker, and Johnson & Johnson.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they represent a small percentage of the total outstanding shares.
• The sale of shares to cover tax obligations is a standard practice and does not indicate any change in the executive's commitment to the company.

Key Dates